ArticleBlood2025

Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome.

Yuning Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.